Palatin to submit LeuTech application

Article

After a successful meeting with the Food and Drug Administration last month, biopharmaceutical firm Palatin Technologies got the go-ahead to file a biologics license application this summer for its monoclonal antibody infection imaging agent,

After a successful meeting with the Food and Drug Administration last month, biopharmaceutical firm Palatin Technologies got the go-ahead to file a biologics license application this summer for its monoclonal antibody infection imaging agent, LeuTech. The company met with the FDA’s Center for Biologic Evaluation and Research in Rockville, MD, and the agency reviewed Palatin’s phase III trial data for LeuTech for the diagnosis of equivocal appendicitis. Palatin hopes LeuTech will be available for sale by mid-summer 2000.

The FDA’s permission to proceed further enhances the Princeton, NJ, company’s R&D momentum, as it comes on the heels of the company’s May 17 announcement that it had signed a letter of intent for a marketing alliance with St. Louis-based Mallinckrodt (SCAN 5/26/99).

© 1999 Miller Freeman, Inc.All rights reserved.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.